(Q36630021)

15 August 2017

1 reference

title

Multifunctional drugs with different CNS targets for neuropsychiatric disorders (English)

1 reference

15 August 2017

3

Moussa B H Youdim

1 reference

15 August 2017

Cornelis J Van der Schyf

series ordinal

1

object named as

Cornelis J Van der Schyf

1 reference

15 August 2017

Werner J Geldenhuys

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

18 October 2006

1 reference

Journal of Neurochemistry

15 August 2017

published in

1 reference

15 August 2017

volume

99

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

1033-1048

1 reference

Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Novel dual inhibitors of calpain and lipid peroxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Discovery and structure-activity relationships of novel selective norepinephrine and dual serotonin/norepinephrine reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Rational design and enantioselective synthesis of (1R,4S,5R,6S)-3-azabicyclo[3.3.0]octane-4,6-dicarboxylic acid - a novel inhibitor at human glutamate transporter subtypes 1, 2, and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Late-life depression: a neuropsychiatric approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

The role of dihydropyridine-sensitive voltage-gated calcium channels in potassium-mediated neuronal survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

New developments in iron chelators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Is Transduced into Cellular Responses in Neurons: Ca2+Signals and Neurotransmitter Release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Caffeine as a neuroprotective adenosine receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

In vitro antioxidant neuroprotective activity of BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Iron regulatory proteins and the molecular control of mammalian iron metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

A nitric oxide releasing derivative of flurbiprofen inhibits experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Negative attitude towards medication is associated with working memory impairment in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Animal models of stroke: do they have value for discovering neuroprotective agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Apomorphine protects against MPTP-induced neurotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Evaluation of memantine for neuroprotection in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Rational drug design and the discovery of the delta2-1,2,3-triazolines, a unique class of anticonvulsant and antiischemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Multicomponent therapeutics for networked systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

NMDA receptor pathways as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Does caffeine intake protect from Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa-cyclo[6.5.0.0(3,7).0(4,12).0(5,10).0(9,13]tridecane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Statins--a cure-all for the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

21 January 2018

Risperidone: a review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Designed multiple ligands. An emerging drug discovery paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

From magic bullets to designed multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Mechanisms of action of cognitive enhancers on neuroreceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Evaluation of drugs acting at glutamate transporters in organotypic hippocampal cultures: new evidence on substrates and blockers in excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

ITH4012 (ethyl 5-amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzol[1,8]naphthyridine-3-carboxylate), a novel acetylcholinesterase inhibitor with "calcium promotor" and neuroprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Iron metabolism and the IRE/IRP regulatory system: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Neuronal protective effects of calcium antagonists in cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Monoamine oxidase-B inhibition in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Metal and inflammatory targets for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Combination therapy in Alzheimer's disease: a review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibiti

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Recent developments in the drug treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Epidemiology of post-stroke dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Comparison of the effects of cholinesterase inhibitors on [3H]MK-801 binding in rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Iron, brain ageing and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2006.04141.X

10.1111/J.1471-4159.2006.04141.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference